Yan Leyfman: AI’s Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on X:
“In a study led by Dr. MLK Chua and team, a deep learning model shows promise in transforming how we assess tumor-infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC).
Using HnE-stained slides, this AI-driven approach (TILDL) accurately quantifies TILs, predicting survival outcomes and response to immunotherapy.
- Higher TILDL % = better 5-year survival in early-stage NPC
- In metastatic NPC, TILDL % predicts improved response to immune checkpoint blockade (ICB)
- Potential biomarker to personalize treatment
This work highlights AI’s role in streamlining pathology and guiding immunotherapy decisions in NPC.”
Title: Deep learning-based quantification of tumor-infiltrating lymphocytes as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings
Authors: T. Lu, F. Xie, Y. Hu, S. Zhan, F. Zhong, J. Chen, J. Pan, X. Gong, Z. Liu, C. Huang, C. Xie, Q. Guo, M.L.K. Chua, J. Li
You can read the Full Article on Elsevier.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023